ArticleMedicine2026
35 blood and urine biomarkers and digestive system cancers: A two-sample Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Digestive system cancers (DSCs) are globally prevalent and account for a substantial proportion of cancer-related deaths. This study aimed to investigate the potential causal relationships between 35 blood and urine biomarkers and the risk of 4 major DSCs, including esophageal, gastric, colorectal, and pancreatic cancers. A 2-sample bidirectional Mendelian randomization (MR) approach was employed. Genome-wide association studies (GWAS) summary statistics for DSCs were obtained from public databases, and biomarker data were sourced from a GWAS meta-analysis of the UK Biobank. The inverse variance weighted (IVW), MR-Egger, and weighted median methods were used to examine causality. To evaluate robustness, we performed sensitivity analyses, including Cochran Q test for heterogeneity, MR-Egger and MR-PRESSO tests for pleiotropy, and leave-one-out analysis. Furthermore, reverse MR analyses were conducted for all significant causal relationships identified. We identified 14 significant associations: 6 with esophageal cancer, 1 with gastric cancer, 3 with colorectal cancer, and 4 with pancreatic cancer. Elevated serum uric acid was associated with increased pancreatic cancer risk (odds ratio [OR] = 1.230, 95% confidence interval [CI]: 1.015-1.490, P = .035) but decreased esophageal cancer risk (OR = 0.822, 95% CI: 0.683-0.989, P = .038). Increased insulin-like growth factor (IGF-1) levels were associated with higher risks of esophageal (OR = 1.228, 95% CI: 1.035-1.457, P = .019) and colorectal cancer (OR = 1.216, 95% CI: 1.125-1.314, P < .001). Subsequent sensitivity analyses revealed that our results were rarely influenced by pleiotropy or heterogeneity. Reverse MR analysis indicated that there were no causal associations between genetic predisposition to DSCs and the identified biomarkers. The identified biomarkers may serve as potential diagnostic markers, aiding in the early detection of cancer, which is crucial for improving treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.